CN104936951B - 作为激酶抑制剂的苯并咪唑衍生物 - Google Patents

作为激酶抑制剂的苯并咪唑衍生物 Download PDF

Info

Publication number
CN104936951B
CN104936951B CN201380067040.1A CN201380067040A CN104936951B CN 104936951 B CN104936951 B CN 104936951B CN 201380067040 A CN201380067040 A CN 201380067040A CN 104936951 B CN104936951 B CN 104936951B
Authority
CN
China
Prior art keywords
alkyl
independently selected
substituents
substituted
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380067040.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104936951A (zh
Inventor
沃伊切赫·察尔迪邦
克日什托夫·布若佐卡
米夏尔·加莱佐夫斯基
雷娜塔·温达克
马里乌什·米利克
玛格达莱娜·扎瓦兹卡
帕维尔·古济克
埃韦利纳·温恰
玛尔塔·普罗科普
卡塔日娜·维克利克
亚历山德拉·萨比尼亚日
维斯瓦夫·马雷克·乔洛迪
雷蒙德·霍尔瓦特
托马斯·日姆斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruiwu Treatment Co ltd
Original Assignee
Selvita Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sp zoo filed Critical Selvita Sp zoo
Publication of CN104936951A publication Critical patent/CN104936951A/zh
Application granted granted Critical
Publication of CN104936951B publication Critical patent/CN104936951B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CN201380067040.1A 2012-12-21 2013-12-20 作为激酶抑制剂的苯并咪唑衍生物 Active CN104936951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors
GB1223265.8 2012-12-21
PCT/EP2013/077754 WO2014096388A2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN104936951A CN104936951A (zh) 2015-09-23
CN104936951B true CN104936951B (zh) 2018-02-06

Family

ID=47682482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067040.1A Active CN104936951B (zh) 2012-12-21 2013-12-20 作为激酶抑制剂的苯并咪唑衍生物

Country Status (23)

Country Link
US (2) US9388192B2 (enExample)
EP (1) EP2935244B1 (enExample)
JP (1) JP6169185B2 (enExample)
KR (1) KR101779272B1 (enExample)
CN (1) CN104936951B (enExample)
AU (1) AU2013366513B2 (enExample)
BR (1) BR112015014701B8 (enExample)
CA (1) CA2896156C (enExample)
CY (1) CY1120692T1 (enExample)
DK (1) DK2935244T3 (enExample)
ES (1) ES2688395T3 (enExample)
GB (1) GB201223265D0 (enExample)
HR (1) HRP20181429T8 (enExample)
HU (1) HUE039376T2 (enExample)
IL (1) IL239193A0 (enExample)
LT (1) LT2935244T (enExample)
MX (1) MX369589B (enExample)
PL (1) PL2935244T3 (enExample)
PT (1) PT2935244T (enExample)
RS (1) RS57658B1 (enExample)
SI (1) SI2935244T1 (enExample)
SM (1) SMT201800473T1 (enExample)
WO (1) WO2014096388A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
TN2016000270A1 (en) 2014-01-14 2017-10-06 Millennium Pharm Inc Heteroaryls and uses thereof.
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
CN111417394B (zh) 2017-10-19 2023-11-07 帝人制药株式会社 苯并咪唑衍生物及其用途
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2021096314A1 (ko) * 2019-11-15 2021-05-20 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
CN113491691B (zh) * 2020-04-02 2023-04-14 深圳贝瑞生物医药科技有限公司 一种用于制备抗肿瘤药物或14-3-3η蛋白抑制剂的化合物
KR102854745B1 (ko) * 2020-04-23 2025-09-04 진크래프트 주식회사 R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
CN119836291A (zh) 2022-07-29 2025-04-15 雷沃医疗有限公司 包含bcl-2抑制剂的癌症组合疗法
JP2025523941A (ja) 2022-07-29 2025-07-25 アールワイヴィーユー セラピューティクス エス．エー． Ｆｌｔ３阻害剤を含む癌併用療法
CN120826396A (zh) * 2023-03-06 2025-10-21 英矽智能科技(上海)有限公司 Cdk8/19双重抑制剂及其使用方法
CN120004808B (zh) * 2023-11-15 2025-11-25 宜昌人福药业有限责任公司 一种2-溴-5,6-二氯-1h-苯并咪唑的制备方法
WO2026132392A1 (en) 2024-12-20 2026-06-25 Berlin-Chemie Ag Cancer therapy of subjects carrying mutations in a splicing factor gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1469504A (fr) * 1964-10-22 1967-02-17 Fisons Pest Control Ltd Composés insecticides
DE3227893A1 (de) * 1982-07-26 1984-01-26 Macherey-Nagel & Co Chemikalienhandel, 5160 Düren Verwendung von benzimidazolderivaten zum nachweis von blut und anderen peroxidatisch wirksamen substanzen in koerperfluessigkeiten und ausscheidungsprodukten, insbesondere als diagnostikum in form eines testpapiers
GB9600142D0 (en) 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
AU744939B2 (en) * 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
DK1133477T3 (da) * 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
EP1891048A1 (en) 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
WO2014037340A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
MX2015007057A (es) 2016-01-20
BR112015014701B8 (pt) 2022-12-13
US20150336967A1 (en) 2015-11-26
RS57658B1 (sr) 2018-11-30
ES2688395T3 (es) 2018-11-02
CY1120692T1 (el) 2019-12-11
AU2013366513A1 (en) 2015-06-11
US9388192B2 (en) 2016-07-12
MX369589B (es) 2019-11-13
IL239193A0 (en) 2015-07-30
GB201223265D0 (en) 2013-02-06
KR20150095908A (ko) 2015-08-21
US20170152249A1 (en) 2017-06-01
SI2935244T1 (sl) 2019-01-31
PL2935244T3 (pl) 2019-02-28
HRP20181429T8 (hr) 2018-12-28
SMT201800473T1 (it) 2018-11-09
AU2013366513B2 (en) 2016-09-01
BR112015014701A2 (pt) 2017-07-11
CA2896156C (en) 2018-05-22
EP2935244B1 (en) 2018-06-27
JP2016503779A (ja) 2016-02-08
JP6169185B2 (ja) 2017-07-26
CA2896156A1 (en) 2014-06-26
WO2014096388A2 (en) 2014-06-26
HUE039376T2 (hu) 2018-12-28
PT2935244T (pt) 2018-10-22
HRP20181429T1 (hr) 2018-11-30
LT2935244T (lt) 2018-10-25
US10174013B2 (en) 2019-01-08
EP2935244A2 (en) 2015-10-28
KR101779272B1 (ko) 2017-09-18
CN104936951A (zh) 2015-09-23
BR112015014701B1 (pt) 2022-11-01
WO2014096388A3 (en) 2014-08-21
DK2935244T3 (en) 2018-09-10

Similar Documents

Publication Publication Date Title
KR101779272B1 (ko) 키나제 억제제로서의 신규 벤즈이미다졸 유도체
CN114555588B (zh) 作为axl抑制剂的喹唑啉类化合物
US10351578B2 (en) Heterocyclic-substituted pyridinopyrimidinone derivative as CDK inhibitor and use thereof
CN101370803B (zh) 作为组蛋白脱乙酰酶抑制剂的取代的吲哚基-烷基-氨基衍生物
EP2498607B1 (en) Kinase inhibitors
AU2005266312B2 (en) Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP2499117B1 (en) A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
RU2581834C1 (ru) Новое пиперидиновое соединение или его соль
TW200829583A (en) Anilinopiperazine derivatives and methods of use thereof
WO2005063293A1 (ja) Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤
WO2014040549A1 (zh) 炔杂芳环化合物及其应用
ES2930106T3 (es) Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa
WO2018153293A1 (zh) 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
WO2017114383A1 (zh) 一类新型的egfr野生型和突变型的激酶抑制剂
JP7594274B2 (ja) 難聴の予防および／または治療用医薬組成物
JP2024533121A (ja) 混合系統キナーゼ阻害薬および使用方法
WO2025181828A1 (en) Triamino pyrimidine compounds as cdk7 inhibitors and methods thereof
Di Maria Development of novel pyrazolo [3, 4-d] pyrimidines as anticancer agents: synthesis of potent c-Src/Abl inhibitors
PT1781639E (pt) Derivados de indolil alquil amina substituídos como novos inibidores de histona-desacetilase
HK1128285B (en) Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20150923

Assignee: Berlin chemistry limited-liability company

Assignor: Selvita Sp. Z. O. O.

Contract record no.: 2017990000476

Denomination of invention: Benzimidazole derivatives as kinase inhibitors

License type: Exclusive License

Record date: 20171204

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Krakow

Patentee after: Ruiwu treatment Co.,Ltd.

Address before: Krakow

Patentee before: SELVITA S.A.

CP01 Change in the name or title of a patent holder